An Open-Label, Randomized, Fasting Condition, Single-dose, Cross-over Study to Evaluate the Bioequivalence "DA-5215 Tab" and "DA-5215-R Tab" in Healthy Volunteers

Fecha de inicio: 1 de mayo de 2022

Inclusion Criteria: 1. A person who aged 19 or older at the time of screening 2. BMI of 18 to 30 (BMI calculation: kg/m2) \- Males weighing 50kg or more, Females weighing 45kg or more 3. No congenital or chronic diseases or pathological symptoms 4. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination 5. A person who agreed to use contraception from the first administration of IP to a week after the last administration of IP 6. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature Exclusion Criteria: 1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to the first administration of IP 2. A person who has participated in other clinical trials within six months prior to the first administration of the IP 3. A person who has had whole blood transfusion within 8 weeks or the apheresis within 2 weeks before the first administration of IP 4. A person who has medical history of gastric resection that can affect the drug absorption 5. A person with a history of regular alcohol intake within a month prior to the first administration of the IP: * Male: More than 21 cups/week * Female: More than 14 cups/week (1 cup: 50 ml of soju, 250 ml of beer, 30ml of spirits) 6. A person who is hypersensitive to any of the IP components 7. A person who has medical history of mental disease 8. A person who is judged not to be suitable for the study by the investigator 9. Lactating or possibly pregnant women